Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

PhIII Crohn's drug

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A right of an oral antisense DNA oligonucleotide drug. The asset comprises of phase III trial drug producing assets targeting Smad7 mRNA for the treatment of moderate-to-severe Crohn's disease (CD) and other indications.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 33 Sir John Rogerson's Quay
  • Dublin 2
  • Ireland

PhIII Crohn's drug Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore PhIII Crohn's drug‘s full profile, request access.

Request full access to PitchBook

PhIII Crohn's drug Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore PhIII Crohn's drug‘s full profile, request access.

Request full access to PitchBook